FIELD: pharmaceutics.
SUBSTANCE: invention relates to compounds selected from 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-amino-3-oxo-propyl)-25-chloro-17-(1H-indole-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03.8]pentacose-1(21),3,5,7,22,24-hexaen-22-yl]benzoic acid; 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03.8]pentacose-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acids; 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-25-chloro-17-(1H-indol-3-ylmethyl)-16-methyl-12.15,18-trioxo-2-thia-4,7,10,13,16,19-hexaazatricyclo[19.4.0.03.8]pentacose-1(21),3,5,7,22,24-hexaen-22-yl]benzoic acid; 2-chloro-4-[rac-(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-25-chloro-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,7,10,13,16,19-hexaazatricyclo[19.4.0.03.8]pentacose-1(21),3,5,7,22, 24-hexaen-22-yl]benzoic acid; 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-25-chloro-17-(1H-indol-3-ylmethyl)-16-methyl-12.15,18-trioxo-2-thia-4,7,10,13,16,19-hexaazatricyclo[19.4.0.03.8]pentacose-1(21),3,5,7,22,24-hexaen-22-yl]-2-fluorobenzoic acid; 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-25-fluoro-17-(1H-indol-3-ylmethyl)-16-methyl-12.15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03.8]pentacose-1(25),3(8),4,6,21,23-hexaene-22-yl]benzoic acid; 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-25-chloro-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03.8]pentacose-1(25),3(8),4,6,21,23-hexaene-22-yl]-2-methylsulfonyl-benzoic acid; 4-[(11S,14S,17S)-14-(4-amino-3,3-difluoro-butyl)-11-(3-aminopropyl)-25-chloro-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentaazatricyclo[19.4.0.03.8]pentacose-1(21),3,5,7,22, 24-hexaen-22-yl]benzoic acid, etc., as well as their pharmaceutically acceptable salts, which are capable of inhibiting the growth of Acinetobacter baumannii bacteria.
EFFECT: invention also relates to a pharmaceutical composition containing the said compounds, a method for inhibiting the growth of Acinetobacter baumannii bacteria, and the use of the compounds to inhibit the growth of Acinetobacter baumannii bacteria or to obtain a drug for inhibiting the growth of Acinetobacter baumannii bacteria.
14 cl, 1 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | 2016 |
|
RU2729609C2 |
| STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | 2015 |
|
RU2680238C2 |
| TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS FOR USING THEM FOR PSMA INHIBITION | 2009 |
|
RU2532912C2 |
| PHENYLPROPANAMIDE DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2017 |
|
RU2738207C2 |
| AMIDE COMPOUND | 2009 |
|
RU2479576C9 |
| LIGAND CONJUGATE WITH CYTOTOXIC DRUG PREPARATION, METHOD AND APPLICATION THEREOF | 2016 |
|
RU2708461C2 |
| SULFONAMIDE-CONTAINING BINDING SYSTEMS FOR MEDICINAL CONJUGATES | 2014 |
|
RU2729194C2 |
| TECHNETIUM AND RHENIUM COMPLEXES WITH BIS(HETEROARYLS) AND METHODS FOR USING THEM | 2009 |
|
RU2539584C2 |
| NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUNDS | 2012 |
|
RU2595136C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2014 |
|
RU2653504C2 |
